Biologics for allergic and immunologic diseases

Area of Science:

• Immunology
• Allergic Diseases
• Pharmacology

Background:

• Biologics and molecularly targeted drugs offer effective, safer short-term alternatives to corticosteroids for immunologic disorders.
• Recent studies in 2021 highlight both the efficacy and novel findings associated with these advanced therapies.

Purpose of the Study:

• To review recent clinical trials on biologics for allergic and immunologic diseases.
• To discuss advancements in understanding the pathophysiology of these conditions.
• To highlight key findings from 2021 research.

Main Methods:

• Review of clinical trials and related research published in 2021.
• Analysis of data on biologics targeting thymic stromal lymphopoietin, IL-33, and IL-33 receptor.
• Evaluation of randomized controlled trials for small-molecule drugs targeting Janus kinase-1.

Main Results:

• Biologics targeting type 2 alarmin cytokines (TSLP, IL-33) are effective in asthma and COPD, also impacting non-type 2 inflammation.
• Oral Janus kinase-1 inhibitors show superiority over dupilumab in treating atopic dermatitis.
• Concerns exist regarding the high cost of biologics and potential disparities in access for racial/ethnic minorities.

Conclusions:

• Biologics and targeted therapies represent significant progress in managing allergic and immunologic diseases.
• Further research is needed to address cost and access barriers to ensure equitable patient benefit.
• Understanding of disease pathophysiology continues to evolve with these therapeutic advancements.